Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 1, 2008, Pages 49-57

  Ambler, Jane ^a,d   Rennie, Robert ^b,d   Poupard, James ^d,e   Koeth, Laura ^d,f   Stass, Heino ^b,d   Endermann, Rainer ^b,d   Choudhri, Shurjeel ^c,d  

^a BAYER CORPORATION   (United States)

^b BAYER PHARMA AG   (Germany)

^c Medical and Scientific Affairs   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e Pharma Institute of Philadelphia   (United States)

^f Laboratory Specialists Inc   (United States)

Author keywords

Anaerobes; Breakpoints; MIC; Moxifloxacin; Susceptibility testing

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLOSTRIDIUM PERFRINGENS; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA, ANAEROBIC; GUIDELINES AS TOPIC; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RATS;

EID: 42049104921     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.01.013     Document Type: Article

References (31)

1. Andrews J.M., Weller T.M., Ashby J.P., Walker R.M., and Wise R. The in vitro activity of ABT773, a new ketolide antimicrobial agent. J. Antimicrob. Chemother. 46 (2000) 1017-1022
2. Bachoual R., Dubreuil L., Soussy C.J., and Tankovic J. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin. Antimicrob. Agents Chemother. 44 (2000) 1842-1845
3. Bartlett J.G., Louie T.J., Gorbach S.L., and Onderdonk A.B. Therapeutic efficacy of 29 antimicrobial regimens in experimental intra-abdominal sepsis. Rev. Infect. Dis. 3 (1981) 535-542
4. Behra-Miellet J., Dubreuil L., and Jumas-Bilak E. Anti-anaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int. J. Antimicrob. Agents 20 (2002) 366-374
5. Cisneros R.L., and Onderdonk A.B. Antimicrobial efficacy testing of moxifloxacin during the peritonitis and abscess formation stages of intra-abdominal sepsis: a controlled trial in the rat model. Curr. Ther. Res. 63 (2002) 821
6. Cisneros R.L., and Onderdonk A.B. Efficacy of moxifloxacin monotherapy versus gatifloxacin monotherapy, piperacillin-tazobactam combination therapy, and clindamycin plus gentamicin combination therapy: an experimental study in a rat model of intra-abdominal sepsis inducted by fluoroquinolone-resistant Bacteroides fragilis. Curr. Ther. Res. 66 (2005) 222-229
7. Cisneros R.L., Bawdon R.E., and Onderdonk A.B. Efficacy of ampicillin/sulbactam for treatment of experimental intra-abdominal sepsis. Curr. Ther. Res. Clin. Exp. 458 (1990) 1021-1029
8. Clinical and Laboratory Standards Institute. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Standard. 2nd ed. (2001), Clinical and Laboratory Standards Institute, Wayne, PA
9. Dorlemann S., Haas M., Wischnewski T., and Freiberg C. Mate efflux systems in Bacteroides fragilis group strains are of minor importance in the development of resistance to moxifloxacin. Bayer HealthCare Pharm. (2006) PH-34314
10. Eckhardt C. Therapeutic efficacy of moxifloxacin in a murine model of severe systemic mixed infection with Escherichia coli and Bacteroides fragilis. Anaerobe 9 (2003) 157-160
11. Goldstein E.J.C., Citron D.M., Warren Y.A., Tyrrell K.L., Verni Merriam C., and Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 50 (2006) 148-155
12. Hecht D.W., and Osmolski J.R. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob. Agents Chemother. 47 (2003) 910-916
13. Herin O., Hedberg M., and Edlund C. Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group. Anaerobe 8 (2002) 277
14. Hoellman D.B., Kelly L.M., Jacobs M.R., and Appelbaum P.C. Comparative anti-anaerobic activity of BMS 284756. Antimicrob. Agents Chemother. 45 (2001) 589-592
15. Kleinkauf N., Ackermann G., Schaumann R., and Rodloff A.C. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob. Agents Chemother. 45 (2001) 1896-1899
16. Malangoni M.A., Song J., Herrington J., Choudhri S., and Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann. Surg. 244 (2006) 204-211
17. Noel A.R., Bowker K.E., and MacGowan A.P. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 49 (2005) 4234-4239
18. Oh H., El Amin N., Davies T., Appelbaum P.C., and Edlund C. GyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob. Agents Chemother. 45 (2001) 1977-1981
19. Peterson M.L., Rotschafer J.C., and Piddock L.J. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis. J. Antimicrob. Chemother. 52 (2003) 481-484
20. Rafii F., Park M., and Novak J.S. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob. Agents Chemother. 49 (2005) 488-492
21. Ricci V., and Piddock L. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones. J. Antimicrob. Chemother 52 (2003) 605-609
22. Ricci V., Peterson M.L., Rotschafer J.C., Wexler H., and Piddock L.J. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob. Agents Chemother. 48 (2004) 1344-1346
23. Rombout F. Investigation on population pharmacokinetics of moxifloxacin (BAY 12-8039), a multi study evaluation using data from studies, 101-108, 110, 111, 113, 115, 117, 120, 123, 132, 133, 135-137, 139, 141-144, 146, 148, 149, 154-157 by non-compartmental mixed effect modelling. Bayer HealthCare Pharm. (1998) 1-229 (Report No. PH-28008)
24. Stass H., and Dalhoff A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection S2 (2005) 29-35
25. Stass H., and Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J. Antimicrob. Chemother. 43 (1999) 83-90
26. Stass H., Rink D., Delesen H., Kubitz D., and Vestweber K. Pharmacokinetics (PK) and peritoneal penetration of moxifloxacin (MFX) during peritonitis. J. Chemother. 17 Suppl. 3 (2005) 01-09
27. Sullivan J., Dain B., and Testa M. Safety, tolerability, and pharmacokinetics of oral BAY 12-8039 400 mg qd for 10 days in healthy volunteers. Bayer HealthCare Pharmaceuticals (1997) 1-579 (Report No. MMRR-1387)
28. Teng L.J., Hsueh P.R., Tsai J.C., Liaw S.J., Ho S.W., and Luh K.T. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob. Agents Chemother. 46 (2002) 2908-2913
29. Thadepalli H., Chuah S.K., and Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 50 (2004) 76-80
30. Weinstein W.M., Onderdonk A.B., Bartlett J.G., and Gorbach S.L. Experimental intra-abdominal abscesses in rates: development of an experimental model. Infect. Immun. 10 (1974) 1250-1255
31. Wischnewski T., Hass M., Dorlemann S., and Freiberg C. Mechanism of quinolone resistance in Bacteroides fragilis and determination of mutant prevention concentrations. Bayer HealthCare Pharm. (2006) 3-10